Senseonics (NYSE:SENS) Receives “Buy” Rating from HC Wainwright

Senseonics (NYSE:SENS)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $2.00 price target on the stock.

Separately, StockNews.com started coverage on Senseonics in a report on Friday, November 8th. They issued a “sell” rating for the company.

Senseonics Price Performance

NYSE SENS opened at $0.28 on Friday. Senseonics has a 12-month low of $0.28 and a 12-month high of $0.75. The firm’s 50 day moving average is $0.35 and its 200-day moving average is $0.40. The company has a market capitalization of $168.13 million, a PE ratio of -2.18 and a beta of 0.79. The company has a quick ratio of 2.89, a current ratio of 2.47 and a debt-to-equity ratio of 59.17.

Institutional Investors Weigh In On Senseonics

A number of institutional investors and hedge funds have recently modified their holdings of SENS. State Board of Administration of Florida Retirement System acquired a new position in shares of Senseonics in the first quarter valued at $91,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Senseonics by 30.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after acquiring an additional 211,128 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after purchasing an additional 51,000 shares during the last quarter. Vanguard Group Inc. increased its position in Senseonics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after buying an additional 155,715 shares during the period. Finally, Virtu Financial LLC acquired a new stake in Senseonics in the 1st quarter worth about $162,000. 12.36% of the stock is owned by institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.